恆基達鑫(002492.SZ):子公司擬參設大健康產業併購投資基金
格隆匯 12 月 10日丨恆基達鑫(002492.SZ)公佈,近日,公司子公司珠海橫琴新區恆投創業投資有限公司(“恆投創投”)與廣州博濟醫藥生物技術股份有限公司(“博濟醫藥”)的全資子公司廣東廣濟投資有限公司(“廣濟投資”)、贛江新區管委會控股平台江西贛江新區開發投資集團有限責任公司(“贛江新區開發投資集團”)、廣州趣道資產管理有限公司(“趣道資管”)簽署了《贛江新區博趣投資管理合夥企業(有限合夥)合夥協議》,共同發起設立贛江新區博趣投資管理合夥企業(有限合夥)大健康投資併購基金,本期基金總認繳出資額為1億元,其中贛江新區開發投資集團以自有資金出資8500萬元,佔出資總額85%、廣濟投資出資900萬元,佔出資總額9%、恆投創投擬出資500萬元,佔出資總額5%、趣道資管出資100萬元,佔出資總額1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.